Literature DB >> 3265419

High-performance liquid chromatographic assay for the simultaneous monitoring of mefloquine and its acid metabolite in biological samples using protein precipitation and ion-pair extraction.

Y Bergqvist1, U Hellgren, F C Churchill.   

Abstract

A high-performance liquid chromatographic (HPLC) method is presented for the simultaneous determination of mefloquine and its acid metabolite in plasma and whole blood. Plasma and whole blood are deproteinized with a combination of zinc and acetonitrile before extraction. Mefloquine and its acid metabolite are extracted simultaneously at pH 4 by methyl tert.-butyl ether, where mefloquine is extracted as an ion pair with heptanesulphonate. After evaporation of the organic phase, the residue is dissolved in mobile phase and injected on to the chromatographic column. A reversed-phase column (Spherisorb ODS-1) is used with acetonitrile-phosphate buffer (0.1 mol/l, pH 2.5) (42:58) containing 40 mmol/l perchlorate as the mobile phase. N,N-Dioctylamine was added to the mobile phase to give a concentration of 0.1% and the pH was adjusted to 2.3-2.7 with concentrated phosphoric acid. The method permits the determination of 0.10 mumol/l (30 ng/ml) mefloquine and its acid metabolite in plasma. The coefficient of variation was 5-6% at the therapeutic level (mefloquine 1-4 mumol/l, its carboxylic metabolite 2-6 mumol/l) in 0.5-ml samples. An alternative method is also described with a similar clean-up procedure that uses protein precipitation with zinc-acetonitrile as a sample pretreatment for therapeutic monitoring of mefloquine and metabolite in plasma and whole blood. Using this method, 0.25 mumol/l mefloquine and its metabolite can be determined. The results from the two methods correlate well.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265419     DOI: 10.1016/s0378-4347(00)80650-7

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Authors:  B G Charles; A Blomgren; P E Nasveld; S J Kitchener; A Jensen; R M Gregory; B Robertson; I E Harris; M P Reid; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  2007-01-11       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

3.  Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.

Authors:  Y Khaliq; K Gallicano; C Tisdale; G Carignan; C Cooper; A McCarthy
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

4.  Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

Authors:  Gabriel Carrasquilla; Clemencia Barón; Edwin M Monsell; Marc Cousin; Verena Walter; Gilbert Lefèvre; Oliver Sander; Laurel M Fisher
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

5.  Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine.

Authors:  A L Fontanet; B D Johnston; A M Walker; Y Bergqvist; U Hellgren; W Rooney
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

6.  Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study.

Authors:  C A Crevoisier; I Joseph; M Fischer; H Graf
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

7.  Patient age does not affect mefloquine concentrations in erythrocytes and plasma during the acute phase of falciparum malaria.

Authors:  José Luiz Fernandes Vieira; Larissa Maria Guimarães Borges; Michelle Valéria Dias Ferreira; Juan Gonzalo Bardarez Rivera; Margarete do Socorro Mendonça Gomes
Journal:  Braz J Infect Dis       Date:  2016-08-16       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.